How should I start and monitor fezolinetant 45 mg daily for a post‑menopausal woman with moderate‑to‑severe vasomotor symptoms, given hepatic function, CYP3A4 drug interactions, and pregnancy/breastfeeding considerations?

Starting and Monitoring Fezolinetant 45 mg Daily for Moderate‑to‑Severe Vasomotor Symptoms

Baseline Hepatic Assessment (Mandatory Before First Dose)

Fezolinetant is absolutely contraindicated if baseline ALT or AST ≥ 2× ULN or total bilirubin ≥ 2× ULN; do not initiate therapy until transaminases and bilirubin normalize. 1

• Obtain baseline ALT, AST, and total bilirubin before prescribing the first dose—this is an FDA‑mandated requirement following postmarketing reports of hepatotoxicity and jaundice. 1
• Known cirrhosis is an absolute contraindication to fezolinetant; verify absence of cirrhosis through history, imaging, or prior liver biopsy before initiation. 1

Renal Function Screening

• Severe renal impairment (eGFR < 30 mL/min/1.73 m²) or end‑stage renal disease are absolute contraindications; measure serum creatinine and calculate eGFR before starting therapy. 1

CYP1A2 Inhibitor Drug Interaction (Absolute Contraindication)

Concomitant use of fezolinetant with any CYP1A2 inhibitor is absolutely contraindicated by the FDA. 1

• Screen for current use of strong or moderate CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin, enoxacin) before prescribing fezolinetant; if the patient is taking any CYP1A2 inhibitor, do not start fezolinetant. 1
• Smoking is a moderate CYP1A2 inducer and does not require dose adjustment—no clinically significant differences in fezolinetant exposure were observed in smokers. 1

Dosing Regimen

• Prescribe fezolinetant 45 mg orally once daily, with or without food, as the standard therapeutic dose for moderate‑to‑severe vasomotor symptoms. 1, 2, 3
• Fezolinetant 45 mg reduced the frequency of moderate‑to‑severe hot flashes by approximately 2.5 events per day compared with placebo at week 12, with improvement observed as early as week 1. 2, 4
• The 45 mg dose also significantly reduced vasomotor symptom severity (mean difference ≈ –0.29 to –0.40 on severity scales) and improved sleep disturbance scores (PROMIS SD‑SF 8b) by week 24. 2, 3

Mandatory Hepatic Monitoring Schedule

Perform follow‑up hepatic laboratory tests (ALT, AST, total bilirubin) monthly for the first 3 months, then at 6 months and 9 months after initiation. 1

• If transaminase elevations exceed 3× ULN at any time, increase monitoring frequency until values resolve. 1
• Discontinue fezolinetant immediately if transaminases rise above 5× ULN, or if transaminases exceed 3× ULN and total bilirubin exceeds 2× ULN. 1
• Instruct patients to stop fezolinetant immediately and seek urgent medical evaluation (including hepatic laboratory tests) if they develop new‑onset fatigue, decreased appetite, nausea, vomiting, pruritus, jaundice, pale stools, dark urine, or abdominal pain. 1

Pregnancy and Breastfeeding Considerations

• Fezolinetant is indicated only for postmenopausal women; pregnancy status is not relevant in this population, but if a woman of reproductive potential is prescribed fezolinetant off‑label, pregnancy must be excluded before initiation. 1
• No data exist on fezolinetant excretion in human milk or effects on breastfed infants; the drug is not intended for use in lactating women. 1

Efficacy Timeline and Duration

• Symptom improvement (both frequency and severity) is typically observed by week 1 and maintained through 52 weeks of continuous therapy. 2, 4
• Network meta‑analysis data show fezolinetant 45 mg is statistically superior to all non‑hormonal therapies studied (paroxetine 7.5 mg, desvenlafaxine 50–200 mg, gabapentin ER 1800 mg) in reducing vasomotor symptom frequency, and does not differ significantly from most hormone therapy regimens in efficacy. 5

Safety Profile

• Treatment‑emergent adverse events (TEAEs) occurred in approximately 43–65 % of fezolinetant‑treated patients versus 45–61 % with placebo; the most common TEAEs were COVID‑19 (13.3 %), headache (8.8 %), and fatigue (5.8 %). 3, 4
• Serious TEAEs were infrequent (0–4.4 % across trials), and liver enzyme elevations during the first 12 weeks were rare (0–1.2 % of patients) and generally asymptomatic, transient, and resolved on treatment or after discontinuation. 4
• Fezolinetant is not a substrate or inhibitor of P‑glycoprotein, BCRP, OATP1B1, OATP1B3, or major CYP enzymes, minimizing the risk of drug–drug interactions beyond the absolute contraindication with CYP1A2 inhibitors. 1

Clinical Algorithm for Initiation

1. Screen for absolute contraindications: known cirrhosis, severe renal impairment (eGFR < 30), concomitant CYP1A2 inhibitor use. 1
2. Obtain baseline hepatic panel (ALT, AST, total bilirubin) and serum creatinine/eGFR; do not start if ALT/AST ≥ 2× ULN or bilirubin ≥ 2× ULN. 1
3. Prescribe fezolinetant 45 mg once daily with or without food. 1, 2
4. Schedule hepatic monitoring: monthly for months 1–3, then at 6 and 9 months. 1
5. Counsel patient on hepatotoxicity warning signs and instruct immediate discontinuation plus urgent lab testing if symptoms develop. 1
6. Reassess efficacy at week 4; most patients experience meaningful symptom reduction by this time. 2, 4

Common Pitfalls to Avoid

• Do not prescribe fezolinetant to patients taking fluvoxamine, ciprofloxacin, or any other CYP1A2 inhibitor—this is an absolute FDA contraindication. 1
• Do not skip baseline hepatic laboratory tests or the mandatory monthly monitoring during the first 3 months; postmarketing hepatotoxicity cases prompted the FDA boxed warning. 1
• Do not continue fezolinetant if transaminases exceed 5× ULN or if transaminases exceed 3× ULN with bilirubin > 2× ULN; these thresholds mandate immediate discontinuation. 1
• Do not assume fezolinetant is safe in cirrhotic patients—cirrhosis is an absolute contraindication regardless of Child‑Pugh class. 1